These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10202610)

  • 1. Transdermal scopolamine withdrawal syndrome.
    Feder RE
    Clin Neuropharmacol; 1999; 22(2):120. PubMed ID: 10202610
    [No Abstract]   [Full Text] [Related]  

  • 2. [An unusual case of psychosis caused by long-term administration of a scopolamine membrane patch. Paranoid hallucinogenic and delusional symptoms].
    Rubner O; Kummerhoff PW; Haase H
    Nervenarzt; 1997 Jan; 68(1):77-9. PubMed ID: 9132625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scopolamine patch can be confusing to the patient and anesthesiologist: a case report.
    Elias MA; Abouleish E
    Anesthesiology; 1997 Mar; 86(3):743-4. PubMed ID: 9066342
    [No Abstract]   [Full Text] [Related]  

  • 4. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal hyoscine induced unilateral mydriasis.
    Hannon B; Jennings V; Twomey M; O'Reilly M
    BMJ Case Rep; 2012 Mar; 2012():. PubMed ID: 22605696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I heard that the adhesive patch you can wear to prevent motion sickness is available again. Why was it taken off the market?
    Mayo Clin Health Lett; 1998 Mar; 16(3):8. PubMed ID: 9516375
    [No Abstract]   [Full Text] [Related]  

  • 7. Scopolamine withdrawal syndrome.
    Saxena K; Saxena S
    Postgrad Med; 1990 Jan; 87(1):63-6. PubMed ID: 2296571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine.
    Tarkkila P; Törn K; Tuominen M; Lindgren L
    Acta Anaesthesiol Scand; 1995 Oct; 39(7):983-6. PubMed ID: 8848904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scopolamine for prevention of postoperative nausea in gynecologic laparoscopy, a randomized trial.
    Einarsson JI; Audbergsson BO; Thorsteinsson A
    J Minim Invasive Gynecol; 2008; 15(1):26-31. PubMed ID: 18262140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery.
    Harnett MJ; O'Rourke N; Walsh M; Carabuena JM; Segal S
    Anesth Analg; 2007 Sep; 105(3):764-9. PubMed ID: 17717237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review.
    Kranke P; Morin AM; Roewer N; Wulf H; Eberhart LH
    Anesth Analg; 2002 Jul; 95(1):133-43, table of contents. PubMed ID: 12088957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal scopolamine patch with odansetron for the control of nausea after uterine artery embolization compared with odansetron alone: results of a randomized placebo-controlled trial.
    Lee JS; Costantino M; McCullough MF; Lee JB; Jones MM; Carter EA; Spies JB
    J Vasc Interv Radiol; 2010 Jul; 21(7):1018-23. PubMed ID: 20537558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral mydriasis caused by transdermal scopolamine.
    Rubin MM; Sadoff RS; Cozzi GM
    Oral Surg Oral Med Oral Pathol; 1990 Nov; 70(5):569-70. PubMed ID: 2234876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal scopolamine for hyperemesis gravidarum.
    Sagraves R; Anderson DC
    Clin Pharm; 1992 Oct; 11(10):830, 833. PubMed ID: 1341989
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
    Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
    Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting.
    Pergolizzi JV; Philip BK; Leslie JB; Taylor R; Raffa RB
    J Clin Anesth; 2012 Jun; 24(4):334-45. PubMed ID: 22608591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems.
    van der Willigen AH; Oranje AP; Stolz E; van Joost T
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 1):146-7. PubMed ID: 3346401
    [No Abstract]   [Full Text] [Related]  

  • 18. Toxic psychosis from transdermal scopolamine in a child.
    Sennhauser FH; Schwarz HP
    Lancet; 1986 Nov; 2(8514):1033. PubMed ID: 2877187
    [No Abstract]   [Full Text] [Related]  

  • 19. Transdermal scopolamine intoxication in a child.
    Klein BL; Ashenburg CA; Reed MD
    Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169
    [No Abstract]   [Full Text] [Related]  

  • 20. Side effects of transdermal scopolamine.
    Wilkinson JA
    J Emerg Med; 1987; 5(5):389-92. PubMed ID: 3668203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.